The consortium of the RISK-IR project brings together expertise from 13 research groups of 10 institutions from 7 European countries.
Click on their name for further information and on their logo to reach the site of each insitution.
This is achieved by providing impartial advice and authoritative information on health protection issues to the public, communities, professionals and to government. HPA combines public health and scientific expertise, research and emergency planning within the organisation. HPA’s remit covers infectious disease, hazardous chemicals and radiation. The Centre for Radiation, Chemical & Environmental Hazards (CRCE) provides all the specialist research and advice on radiological issues to HPA.
Within the CRCE there is a range of expertise on low dose radiation risk. This spans epidemiology, experimental carcinogenesis, radiation, dosimetry and data analysis. CRCE carries out a substantial portfolio of low dose risk research. Members of staff hold key roles in international advisory bodies such as ICRP, contribute to the UK delegation to UNSCEAR and are regularly asked to provide input into US bodies such as NCRP. HPA is a founding member of MELODI, also HPA-CRCE has a strong track record of contributions to EC low dose risk research including involvement in the FP& EURATOM projects DoReMi and Procardio as well as co-ordination of SOLO.
HPA’s role will be to provide project management (WP1) with Dr Simon Bouffler as co-ordinator. HPA input into RTD activities in WP2 will be lead by Dr Christophe Badie.
Simon Bouffler (project co-ordinator) is head of HPA CRCE’s Biological Effects Department that carries out research that contributes to the identification of radiation and chemical hazards and quantification of risk. The department carries out low dose radiation risk research using animal models and cellular systems. He contributes to the EU DoReMi Network of Excellence as leader of WP5 and has participated in EU EURATOM research under frameworks 5, 6 and 7. Dr Bouffler has been engaged in a number of national and international advisory roles including the HPA Advisory Group on Ionising Radiation, consultant and UK delegation roles for UNSCEAR and contributions to ICRP and NCRP working groups. He has more than 60 relevant scientific publications.
Dr Christophe Badie, leader of HPA’s Cancer Genetics and Cytogenetics, will contribute to RTD activities in WP2. Dr Badie has a track record of research in radiation biology using cellular and animal models. He has worked on a mouse model of radiation included acute myeloid leukaemia for several years. He contributes to the EU DoReMi Network of Excellence and was involved in the FP6 RISC RAD project. He has more than 20 relevant scientific publications.